ID I17RE_HUMAN Reviewed; 667 AA. AC Q8NFR9; B2RB34; B2RNR1; B9EH65; Q6P532; Q8N8H7; Q8N8H8; Q8TEC2; DT 04-DEC-2007, integrated into UniProtKB/Swiss-Prot. DT 01-OCT-2002, sequence version 1. DT 24-JAN-2024, entry version 140. DE RecName: Full=Interleukin-17 receptor E; DE Short=IL-17 receptor E; DE Short=IL-17RE; DE Flags: Precursor; GN Name=IL17RE; ORFNames=UNQ3056/PRO9877; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1). RA Gilbert J.M., Gorman D.M.; RT "Identification of novel IL-17 related receptors."; RL Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1). RX PubMed=12975309; DOI=10.1101/gr.1293003; RA Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., RA Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., RA Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A., RA Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D., RA Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L., RA Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C., RA Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J., RA Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.; RT "The secreted protein discovery initiative (SPDI), a large-scale effort to RT identify novel human secreted and transmembrane proteins: a bioinformatics RT assessment."; RL Genome Res. 13:2265-2270(2003). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 2; 3 AND 4). RC TISSUE=Colon mucosa, Prostate, and Small intestine; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]. RA Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M., RA Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J., RA Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S., RA Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H., RA Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K., RA Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D., RA Hunkapiller M.W., Myers E.W., Venter J.C.; RL Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases. RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 5). RC TISSUE=Lung, Skin, and Testis; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [6] RP TISSUE SPECIFICITY. RX PubMed=16310341; DOI=10.1016/j.cellsig.2005.10.010; RA Li T.-S., Li X.-N., Chang Z.-J., Fu X.-Y., Liu L.; RT "Identification and functional characterization of a novel interleukin 17 RT receptor: a possible mitogenic activation through ras/mitogen-activated RT protein kinase signaling pathway."; RL Cell. Signal. 18:1287-1298(2006). RN [7] RP FUNCTION, AND IDENTIFICATION AS IL17C RECEPTOR. RX PubMed=21993849; DOI=10.1038/ni.2155; RA Song X., Zhu S., Shi P., Liu Y., Shi Y., Levin S.D., Qian Y.; RT "IL-17RE is the functional receptor for IL-17C and mediates mucosal RT immunity to infection with intestinal pathogens."; RL Nat. Immunol. 12:1151-1158(2011). RN [8] RP FUNCTION, IDENTIFICATION AS IL17C RECEPTOR, INTERACTION WITH IL17RA, AND RP TISSUE SPECIFICITY. RX PubMed=21993848; DOI=10.1038/ni.2156; RA Ramirez-Carrozzi V., Sambandam A., Luis E., Lin Z., Jeet S., Lesch J., RA Hackney J., Kim J., Zhou M., Lai J., Modrusan Z., Sai T., Lee W., Xu M., RA Caplazi P., Diehl L., de Voss J., Balazs M., Gonzalez L. Jr., Singh H., RA Ouyang W., Pappu R.; RT "IL-17C regulates the innate immune function of epithelial cells in an RT autocrine manner."; RL Nat. Immunol. 12:1159-1166(2011). CC -!- FUNCTION: Specific functional receptor for IL17C. May be signaling CC through the NF-kappa-B and MAPK pathways. May require TRAF3IP2 /ACT1 CC for signaling. May be a crucial regulator in innate immunity to CC bacterial pathogens. Isoform 2 and isoform 4 may be either cytoplasmic CC inactive or dominant active forms. Isoform 3 and isoform 5 may act as CC soluble decoy receptors. {ECO:0000269|PubMed:21993848, CC ECO:0000269|PubMed:21993849}. CC -!- SUBUNIT: Forms heterodimers with IL17RA; the heterodimer binds IL17C. CC -!- INTERACTION: CC Q8NFR9; Q96F46: IL17RA; NbExp=2; IntAct=EBI-5591275, EBI-5591258; CC -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane {ECO:0000250}; Single- CC pass type I membrane protein {ECO:0000250}. CC -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm {ECO:0000305}. CC -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted {ECO:0000305}. CC -!- SUBCELLULAR LOCATION: [Isoform 4]: Cytoplasm {ECO:0000305}. CC -!- SUBCELLULAR LOCATION: [Isoform 5]: Secreted {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; CC IsoId=Q8NFR9-1; Sequence=Displayed; CC Name=2; CC IsoId=Q8NFR9-2; Sequence=VSP_029190; CC Name=3; CC IsoId=Q8NFR9-3; Sequence=VSP_029193, VSP_029196; CC Name=4; CC IsoId=Q8NFR9-4; Sequence=VSP_029190, VSP_029194, VSP_029195; CC Name=5; CC IsoId=Q8NFR9-5; Sequence=VSP_029191, VSP_029192; CC -!- TISSUE SPECIFICITY: Predominantly expressed in mucosal tissues with CC high levels in keratinocytes and colon epithelial cells. Very low CC expression in dermal fibroblasts. Expressed in various tumor cell CC lines. {ECO:0000269|PubMed:16310341, ECO:0000269|PubMed:21993848}. CC -!- SEQUENCE CAUTION: [Isoform 3]: CC Sequence=BAB85028.1; Type=Frameshift; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF458069; AAM77573.1; -; mRNA. DR EMBL; AY358451; AAQ88816.1; -; mRNA. DR EMBL; AK074238; BAB85028.1; ALT_FRAME; mRNA. DR EMBL; AK096793; BAC04863.1; -; mRNA. DR EMBL; AK096801; BAC04864.1; -; mRNA. DR EMBL; AK314476; BAG37081.1; -; mRNA. DR EMBL; CH471055; EAW64019.1; -; Genomic_DNA. DR EMBL; CH471055; EAW64020.1; -; Genomic_DNA. DR EMBL; CH471055; EAW64016.1; -; Genomic_DNA. DR EMBL; BC063110; AAH63110.1; -; mRNA. DR EMBL; BC137077; AAI37078.1; -; mRNA. DR EMBL; BC137078; AAI37079.1; -; mRNA. DR CCDS; CCDS2589.1; -. [Q8NFR9-1] DR CCDS; CCDS54552.1; -. [Q8NFR9-3] DR RefSeq; NP_001180309.1; NM_001193380.1. [Q8NFR9-3] DR RefSeq; NP_705613.1; NM_153480.1. [Q8NFR9-1] DR RefSeq; NP_705614.1; NM_153481.1. [Q8NFR9-2] DR RefSeq; NP_705616.2; NM_153483.2. DR RefSeq; XP_006713039.1; XM_006712976.1. [Q8NFR9-2] DR AlphaFoldDB; Q8NFR9; -. DR SMR; Q8NFR9; -. DR BioGRID; 126304; 27. DR IntAct; Q8NFR9; 10. DR STRING; 9606.ENSP00000373325; -. DR GlyCosmos; Q8NFR9; 3 sites, No reported glycans. DR GlyGen; Q8NFR9; 3 sites. DR iPTMnet; Q8NFR9; -. DR PhosphoSitePlus; Q8NFR9; -. DR BioMuta; IL17RE; -. DR DMDM; 74730297; -. DR MassIVE; Q8NFR9; -. DR PaxDb; 9606-ENSP00000373325; -. DR PeptideAtlas; Q8NFR9; -. DR ProteomicsDB; 73342; -. [Q8NFR9-1] DR ProteomicsDB; 73343; -. [Q8NFR9-2] DR Antibodypedia; 2563; 341 antibodies from 31 providers. DR DNASU; 132014; -. DR Ensembl; ENST00000383814.8; ENSP00000373325.3; ENSG00000163701.19. [Q8NFR9-1] DR Ensembl; ENST00000454190.6; ENSP00000388086.2; ENSG00000163701.19. [Q8NFR9-3] DR GeneID; 132014; -. DR KEGG; hsa:132014; -. DR MANE-Select; ENST00000383814.8; ENSP00000373325.3; NM_153480.2; NP_705613.1. DR UCSC; uc003btw.4; human. [Q8NFR9-1] DR AGR; HGNC:18439; -. DR CTD; 132014; -. DR DisGeNET; 132014; -. DR GeneCards; IL17RE; -. DR HGNC; HGNC:18439; IL17RE. DR HPA; ENSG00000163701; Tissue enhanced (intestine, skin). DR MIM; 614995; gene. DR neXtProt; NX_Q8NFR9; -. DR OpenTargets; ENSG00000163701; -. DR PharmGKB; PA134896136; -. DR VEuPathDB; HostDB:ENSG00000163701; -. DR eggNOG; ENOG502QU0I; Eukaryota. DR GeneTree; ENSGT00940000161421; -. DR HOGENOM; CLU_026094_0_0_1; -. DR InParanoid; Q8NFR9; -. DR OMA; CVEVYYT; -. DR OrthoDB; 5310632at2759; -. DR PhylomeDB; Q8NFR9; -. DR TreeFam; TF335690; -. DR PathwayCommons; Q8NFR9; -. DR Reactome; R-HSA-448424; Interleukin-17 signaling. DR SignaLink; Q8NFR9; -. DR BioGRID-ORCS; 132014; 12 hits in 1145 CRISPR screens. DR GenomeRNAi; 132014; -. DR Pharos; Q8NFR9; Tbio. DR PRO; PR:Q8NFR9; -. DR Proteomes; UP000005640; Chromosome 3. DR RNAct; Q8NFR9; Protein. DR Bgee; ENSG00000163701; Expressed in skin of leg and 93 other cell types or tissues. DR ExpressionAtlas; Q8NFR9; baseline and differential. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell. DR GO; GO:0005886; C:plasma membrane; TAS:Reactome. DR GO; GO:0030368; F:interleukin-17 receptor activity; IBA:GO_Central. DR GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW. DR Gene3D; 3.40.50.11530; -; 1. DR InterPro; IPR039465; IL-17_rcpt-like. DR InterPro; IPR027841; IL-17_rcpt_C/E_N. DR InterPro; IPR013568; SEFIR_dom. DR PANTHER; PTHR15583; INTERLEUKIN-17 RECEPTOR; 1. DR PANTHER; PTHR15583:SF5; INTERLEUKIN-17 RECEPTOR E; 1. DR Pfam; PF15037; IL17_R_N; 2. DR Pfam; PF08357; SEFIR; 1. DR PROSITE; PS51534; SEFIR; 1. DR Genevisible; Q8NFR9; HS. PE 1: Evidence at protein level; KW Alternative splicing; Cell membrane; Cytoplasm; Glycoprotein; KW Inflammatory response; Membrane; Receptor; Reference proteome; Secreted; KW Signal; Transmembrane; Transmembrane helix. FT SIGNAL 1..23 FT /evidence="ECO:0000255" FT CHAIN 24..667 FT /note="Interleukin-17 receptor E" FT /id="PRO_0000309467" FT TOPO_DOM 24..454 FT /note="Extracellular" FT /evidence="ECO:0000255" FT TRANSMEM 455..475 FT /note="Helical" FT /evidence="ECO:0000255" FT TOPO_DOM 476..667 FT /note="Cytoplasmic" FT /evidence="ECO:0000255" FT DOMAIN 487..624 FT /note="SEFIR" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00867" FT REGION 126..174 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 126..158 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CARBOHYD 318 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 347 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT CARBOHYD 364 FT /note="N-linked (GlcNAc...) asparagine" FT /evidence="ECO:0000255" FT VAR_SEQ 1..116 FT /note="Missing (in isoform 2 and isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_029190" FT VAR_SEQ 268..271 FT /note="YGSD -> CECC (in isoform 5)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_029191" FT VAR_SEQ 272..667 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_029192" FT VAR_SEQ 433..533 FT /note="VWRSDVQFAWKHLLCPDVSYRHLGLLILALLALLTLLGVVLALTCRRPQSGP FT GPARPVLLLHAADSEAQRRLVGALAELLRAALGGGRDVIVDLWEGRHVA -> LHASLS FT SPGGEDAWLIGVGGSVPSGVAVRCPVCLEAPLVSGCLLQTPGALDPGTAGPPHPTGCCS FT GPHLPAPTVRPGPSAASAPPARGGLGGAAAPGGSAG (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_029193" FT VAR_SEQ 433..506 FT /note="VWRSDVQFAWKHLLCPDVSYRHLGLLILALLALLTLLGVVLALTCRRPQSGP FT GPARPVLLLHAADSEAQRRLVG -> ASSWSRHKPTWEEFPSQWGLPSPPAPCFTQLPG FT RRRCLAHRGGGLCALRCGGQMSSLPGSTSCVRMSLTDTWGS (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_029194" FT VAR_SEQ 507..667 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_029195" FT VAR_SEQ 534..667 FT /note="Missing (in isoform 3)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_029196" FT VARIANT 219 FT /note="Y -> C (in dbSNP:rs7356031)" FT /id="VAR_036956" FT VARIANT 402 FT /note="P -> S (in dbSNP:rs9870003)" FT /id="VAR_036957" FT VARIANT 417 FT /note="S -> T (in dbSNP:rs7647642)" FT /id="VAR_036958" FT CONFLICT 270 FT /note="S -> P (in Ref. 3; BAC04864)" FT /evidence="ECO:0000305" FT CONFLICT 445 FT /note="L -> F (in Ref. 3; BAC04864)" FT /evidence="ECO:0000305" SQ SEQUENCE 667 AA; 74810 MW; 1493744E7354067D CRC64; MGSSRLAALL LPLLLIVIDL SDSAGIGFRH LPHWNTRCPL ASHTDDSFTG SSAYIPCRTW WALFSTKPWC VRVWHCSRCL CQHLLSGGSG LQRGLFHLLV QKSKKSSTFK FYRRHKMPAP AQRKLLPRRH LSEKSHHISI PSPDISHKGL RSKRTQPSDP ETWESLPRLD SQRHGGPEFS FDLLPEARAI RVTISSGPEV SVRLCHQWAL ECEELSSPYD VQKIVSGGHT VELPYEFLLP CLCIEASYLQ EDTVRRKKCP FQSWPEAYGS DFWKSVHFTD YSQHTQMVMA LTLRCPLKLE AALCQRHDWH TLCKDLPNAT ARESDGWYVL EKVDLHPQLC FKFSFGNSSH VECPHQTGSL TSWNVSMDTQ AQQLILHFSS RMHATFSAAW SLPGLGQDTL VPPVYTVSQA RGSSPVSLDL IIPFLRPGCC VLVWRSDVQF AWKHLLCPDV SYRHLGLLIL ALLALLTLLG VVLALTCRRP QSGPGPARPV LLLHAADSEA QRRLVGALAE LLRAALGGGR DVIVDLWEGR HVARVGPLPW LWAARTRVAR EQGTVLLLWS GADLRPVSGP DPRAAPLLAL LHAAPRPLLL LAYFSRLCAK GDIPPPLRAL PRYRLLRDLP RLLRALDARP FAEATSWGRL GARQRRQSRL ELCSRLEREA ARLADLG //